Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
申请人:Pfizer Inc.
公开号:US20030195239A1
公开(公告)日:2003-10-16
Compounds of formula I are hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) inhibitors, and are useful in therapeutic and prophylactic treatment of persons infected with hepatitis C virus.
1
method for cyclization of alkynes is described. The reaction cascade involves the intermolecular addition of a phenylthiyl radical to a terminal triple bond generating an alkenylradical, followed by a 1,5-hydrogen atom transfer and a 5-exo-trig radicalcyclization. This very efficient tin-free procedure allows one to prepare highly functionalized cyclopentane derivatives as well as fused bicyclic and